U.S. markets close in 17 minutes
  • S&P 500

    +8.09 (+0.18%)
  • Dow 30

    -52.88 (-0.15%)
  • Nasdaq

    +78.17 (+0.52%)
  • Russell 2000

    +5.90 (+0.26%)
  • Crude Oil

    -0.77 (-0.92%)
  • Gold

    -1.00 (-0.06%)
  • Silver

    -0.24 (-1.00%)

    -0.0027 (-0.23%)
  • 10-Yr Bond

    +0.0400 (+2.44%)

    -0.0041 (-0.30%)

    -0.3340 (-0.29%)

    -3,247.37 (-4.89%)
  • CMC Crypto 200

    -38.66 (-2.52%)
  • FTSE 100

    -32.80 (-0.45%)
  • Nikkei 225

    -546.97 (-1.87%)

Growth Investors: Industry Analysts Just Upgraded Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Revenue Forecasts By 73%

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's forecasts. The analysts have sharply increased their revenue numbers, with a view that Atea Pharmaceuticals will make substantially more sales than they'd previously expected.

After this upgrade, Atea Pharmaceuticals' three analysts are now forecasting revenues of US$1.2b in 2021. This would be a huge improvement in sales compared to the last 12 months. Before the latest update, the analysts were foreseeing US$681m of revenue in 2021. It looks like there's been a clear increase in optimism around Atea Pharmaceuticals, given the very substantial lift in revenue forecasts.

See our latest analysis for Atea Pharmaceuticals


Additionally, the consensus price target for Atea Pharmaceuticals increased 19% to US$69.33, showing a clear increase in optimism from the analysts involved. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. The most optimistic Atea Pharmaceuticals analyst has a price target of US$82.00 per share, while the most pessimistic values it at US$60.00. This shows there is still some diversity in estimates, but analysts don't appear to be totally split on the stock as though it might be a success or failure situation.

The Bottom Line

The most important thing to take away from this upgrade is that analysts lifted their revenue estimates for this year. There was also an increase in the price target, suggesting that there is more optimism baked into the forecasts than there was previously. Seeing the dramatic upgrade to this year's forecasts, it might be time to take another look at Atea Pharmaceuticals.

That's a pretty serious upgrade, but shareholders might be even more pleased to know that forecasts expect Atea Pharmaceuticals to be able to reach break-even within the next few years. For more information, you can click through to our free platform to learn more about these forecasts.

Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies that insiders are buying.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.